The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes
Open accessAbstract
BACKGROUND: Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC). OBJECTIVE: To determine this, we undertook a cross-sectional survey covering 10% of the English population. DESIGN, SETTING, AND PARTICIPANTS: Participants 1-10 yr from diagnosis were identified through national cancer registration data. INTERVENTION: A postal survey was administered containing generic HRQOL and BC-specific outcome measures. Findings were compared with those of the general population and other pelvic cancer patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Generic HRQOL was measured using five-level EQ-5D (EQ-5D-5L) and European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ)-C30. BC-specific outcomes were derived from EORTC QLQ-BLM30 and EORTC QLQ-NMIBC24. RESULTS AND LIMITATIONS: A total of 1796 surveys were completed (response rate 55%), including 868 (48%) patients with non-muscle-invasive BC, 893 (50%) patients who received radiotherapy or radical cystectomy, and 35 (1.9%) patients for whom treatment was unknown. Most (69%) of the participants reported at least one problem in any EQ-5D dimension. Age/sex-adjusted generic HRQOL outcomes were similar across all stages and treatment groups, whilst problems increased with age (problems in one or more EQ-5D dimensions: <65 yr [67% {95% confidence interval or CI: 61-74}] vs 85+ yr [84% {95% CI: 81-89}], p = 0.016) and long-term conditions (no conditions [53% {95% CI: 48-58}] vs more than four conditions [94% {95% CI: 90-97}], p < 0.001). Sexual problems were reported commonly in men, increasing with younger age and radical treatment. Younger participants (under 65 yr) reported more financial difficulties (mean score 20 [95% CI: 16-25]) than those aged 85+ yr (6.8 [4.5-9.2], p < 0.001). HRQOL for BC patients (for comparison, males with problems in one or more EQ-5D dimensions 69% [95% CI: 66-72]) was significantly worse than what has been found after colorectal and prostate cancers and in the general population (51% [95% CI: 48-53], all p < 0.05). CONCLUSIONS: HRQOL following BC appears to be relatively independent of disease stage, treatment, and multimodal care. Issues are reported with sexual function and financial toxicity. HRQOL after BC is worse than that after other pelvic cancers. PATIENT SUMMARY: Patients living with bladder cancer often have reduced quality of life, which may be worse than that for other common pelvic cancer patients. Age and other illnesses appear to be more important in determining this quality of life than the treatments received. Many men complain of sexual problems. Younger patients have financial worries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005 · cited 1×
“EORTC QLQ-C30 consists of five functional scales, three symptom scales, and six single items assessing symptoms (including financial impact and a global scale of quality of life) [25].”
BackgroundEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · cited 12×
“In comparison with the general population and groups with prostate and colorectal cancer, our BC respondents (as a whole) reported more problems across all EQ-5D-5L dimensions, except for anxiety/depression, which was comparable with that for colorectal and prostate cancer (in men; Supplementary Table 7 and Supplement…”
MethodInfluentialValuing health-related quality of life: an EQ-5D-5L value set for England
Devlin, N. J., Shah, K. K., Feng, Y., Mulhern, B., & van Hout, B. (2018) · Health Economics · doi:10.1002/hec.3564 · Cited by 1,356
Cited by
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Epidemiology, Screening, and Prevention of Bladder Cancer
Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S. P., Gupta, S., Smith, A. B., Williams, S. B., & Lotan, Y. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.10.003 · Cited by 372
Catto, J. W. F., Khetrapal, P., Ricciardi, F., Ambler, G., Williams, N. R., Al-Hammouri, T., Khan, M. S., Thurairaja, R., Nair, R., Feber, A., et al. (2022) · JAMA · doi:10.1001/jama.2022.7393 · Cited by 345
Self-citation
Metadata
- Authors
- Catto, J. W. F., Downing, A., Mason, S., Wright, P., Absolom, K., Bottomley, S., Hounsome, L., Hussain, S., Varughese, M., Raw, C., Kelly, P., & Glaser, A. W.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 79
- Issue
- 5
- Pages
- 621-632
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W3126200693
- Cited by
- 172
- References
- 4
- FWCI
- 22.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. https://app.cochat.ai/papers/10.1016/j.eururo.2021.01.032
- The paper
- Catto, J. W. F., Downing, A., Mason, S., Wright, P., Absolom, K., Bottomley, S., Hounsome, L., Hussain, S., Varughese, M., Raw, C., Kelly, P., & Glaser, A. W. (2021). Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. European Urology. https://doi.org/10.1016/j.eururo.2021.01.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.